Compare CTR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ClearBridge Energy MLP Total Return Fund is the United States-based non-diversified, closed-end management investment company. Its investment objective is to provide a high level of total return consisting of cash distributions and capital appreciation.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.